C07D 257/00
Heterocyclic compounds containing rings having four nitrogen atoms as the only ring
Official title: Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
C07D257/00 (Heterocyclic compounds containing rings having four nitrogen atoms as the only ring) appears on 2,780 US grants and 2,189 published applications in this corpus.
Search patents in C07D- Granted patents
- 2,780
- Published applications
- 2,189
- Assignees
- 1,098
- Inventors
- 7,114
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 28 | 0 |
| 1977 | 35 | 0 |
| 1978 | 56 | 0 |
| 1979 | 37 | 0 |
| 1980 | 29 | 0 |
| 1981 | 72 | 0 |
| 1982 | 29 | 0 |
| 1983 | 28 | 0 |
| 1984 | 34 | 0 |
| 1985 | 48 | 0 |
| 1986 | 33 | 0 |
| 1987 | 39 | 0 |
| 1988 | 38 | 0 |
| 1989 | 54 | 0 |
| 1990 | 42 | 0 |
| 1991 | 56 | 0 |
| 1992 | 39 | 0 |
| 1993 | 50 | 0 |
| 1994 | 48 | 0 |
| 1995 | 54 | 0 |
| 1996 | 49 | 0 |
| 1997 | 67 | 0 |
| 1998 | 66 | 0 |
| 1999 | 76 | 0 |
| 2000 | 75 | 0 |
| 2001 | 58 | 6 |
| 2002 | 75 | 64 |
| 2003 | 53 | 87 |
| 2004 | 41 | 99 |
| 2005 | 51 | 96 |
| 2006 | 54 | 95 |
| 2007 | 46 | 101 |
| 2008 | 62 | 96 |
| 2009 | 60 | 94 |
| 2010 | 73 | 94 |
| 2011 | 68 | 71 |
| 2012 | 73 | 95 |
| 2013 | 71 | 84 |
| 2014 | 70 | 90 |
| 2015 | 68 | 91 |
| 2016 | 72 | 103 |
| 2017 | 98 | 84 |
| 2018 | 67 | 78 |
| 2019 | 61 | 92 |
| 2020 | 71 | 97 |
| 2021 | 67 | 94 |
| 2022 | 60 | 81 |
| 2023 | 41 | 88 |
| 2024 | 50 | 88 |
| 2025 | 50 | 76 |
| 2026 | 38 | 45 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Tetraazadodecane based chelating agents for separation of rare earth elements and method therefor6 Oct 2026US 12,752,219 B2Ustav Organicke Chemie A Biochemie Av Cr, V. V. I.
- TEAD inhibitors29 Sep 2026US 12,747,207 B2Orion Corporation
- Process for the manufacture of tetrazole derivatives29 Sep 2026US 12,747,217 B2Hoffmann-La Roche Inc.
- Liposomal formulations comprising AT1 receptor blockers and uses thereof25 Aug 2026US 12,714,669 B2Yissum Research Development Company of the Hebrew University of Jerusalem
- DOTA-hapten compositions for anti-DOTA/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy25 Aug 2026US 12,714,758 B2Memorial Sloan Kettering Cancer Center
- Bicyclic compounds8 Oct 2026US 2026/0308114 A1Vivace Therapeutics, Inc.
- Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications1 Oct 2026US 2026/0297012 A1NucMito Pharmaceuticals Co. Ltd.
- Therapeutic compounds1 Oct 2026US 2026/0297016 A1Regents of the University of Minnesota
- Modulators of sortilin activity24 Sep 2026US 2026/0285802 A1
- Synthesis of prostate specific membrane antigen (psma) ligands24 Sep 2026US 2026/0285818 A1Novartis AG
Most cited
By later US patents
- Diagnostic media413US 4,647,447 ASchering Corporation · 1987
- Detection of analytes in aqueous environments251US 6,794,195 B2Sensors for Medicine and Science, Inc. · 2004
- Method of enhancing NMR imaging using chelated paramagnetic ions bound to biomolecules213US 5,021,236 ASchering Corporation · 1991
- Nitrogen containing heteroaromatics as factor Xa inhibitors211US 6,020,357 ADuPont Pharmaceuticals Company · 2000
- 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs191US 4,885,363 AE. R. Squibb & Sons, Inc. · 1989